China’s Jiangsu Simcere Pharmaceutical Group Limited announced on Friday that it has completed raising nearly 600 million yuan ($94 million) in a Series B round of financing co-led by state-backed conglomerate CITIC Group’s CITIC Securities and CITIC Medical & Health.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
